9 patents
Utility
Neutralizing anti-influenza b antibodies and uses thereof
17 Oct 23
The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages.
Nicole Kallewaard-Lelay, Qing Zhu, Ebony Benjamin, Leslie Wachter, Andy Yuan, Josephine Mary Mcauliffe, Davide Corti, Antonio Lanzavecchia
Filed: 12 Oct 21
Utility
Broadly neutralizing antibodies directed against the rabies virus glycoprotein and uses thereof
22 Aug 23
The invention relates to antibodies, and antigen binding fragments thereof, that potently neutralize infection of both RABV and non-RABV lyssaviruses.
Davide Corti, Hervé Bourhy
Filed: 22 May 20
Utility
Broadly neutralizing antibodies directed against the rabies virus glycoprotein and uses thereof
15 Aug 23
The invention relates to antibodies, and antigen binding fragments thereof, that potently neutralize infection of both RABV and non-RABV lyssaviruses.
Davide Corti, Hervé Bourhy
Filed: 22 May 20
Utility
HIV vaccines comprising one or more population episensus antigens
18 Apr 23
Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach.
Eric Bruening, Klaus Frueh, Louis Picker, Bette T. M. Korber, James Theiler, Emily Marshall
Filed: 31 Aug 20
Utility
HIV vaccines comprising one or more population episensus antigens
17 Jan 23
Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach.
Eric Bruening, Klaus Frueh, Louis Picker, Bette T. M. Korber, James Theiler, Emily Marshall
Filed: 31 Aug 20
Utility
Antibodies against SARS-CoV-2 and methods of using the same
25 Oct 22
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection.
Davide Corti, Katja Fink, Martina Beltramello, Elisabetta Cameroni, Dora Pinto, Gyorgy Snell, Florian A. Lempp, Amalio Telenti
Filed: 23 Jul 21
Utility
Coronavirus iRNA compositions and methods of use thereof
28 Dec 21
The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the coronavirus genome.
Akin Akinc, James D. McIninch, Yesseinia Anglero-Rodriguez, Mark K. Schlegel, Christy M. Hebner, Florian A. Lempp
Filed: 17 May 21
Utility
Antibodies against SARS-CoV-2 and methods of using the same
9 Nov 21
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection.
Davide Corti, Katja Fink, Martina Beltramello, Elisabetta Cameroni, Dora Pinto, Gyorgy Snell, Florian A. Lempp, Amalio Telenti
Filed: 25 Feb 21
Utility
HIV vaccines comprising one or more population episensus antigens
19 Jan 21
Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach.
Eric Bruening, Klaus Frueh, Louis Picker, Bette T. M. Korber, James Theiler, Emily Marshall
Filed: 5 Oct 15
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first